European Commission Greenlights Vimseltinib for Symptomatic, Unresectable TGCT | OncLive Vimseltinib earned approval from the European Commission for the treatment of symptomatic, unresectable tenosynovial giant cell tumor.

European Commission Greenlights Vimseltinib for Symptomatic, Unresectable TGCT
#TGCT #EuropeApproval
www.onclive.com/view/europea...